Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to Thrombosis
- 1 March 2007
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (9) , 891-893
- https://doi.org/10.1056/nejmp068309
Abstract
In 1949, Ackroyd reported the abrupt onset of severe thrombocytopenia and purpura in patients receiving the sedative allylisopropylacetylcarbamide (Sedormid).1 All the patients had taken Sedormid previously and had become sensitized to it. Today, this classic picture of drug-induced, immune-mediated thrombocytopenia is most often caused by quinine in outpatients and by vancomycin in hospitalized patients, as discussed by Von Drygalski et al. in this issue of the Journal (pages 904–910).In 1973, Rhodes, Dixon, and Silver described thrombocytopenia and thrombosis occurring a week after the initiation of heparin therapy and provided evidence of an immune pathogenesis for this complication of heparin . . .Keywords
This publication has 3 references indexed in Scilit:
- Vancomycin-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007
- Platelet Immunopathology and Therapy: A Canadian Blood Services Research and Development SymposiumTransfusion Medicine Reviews, 2006
- Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitorsJournal of Thrombosis and Haemostasis, 2006